KNEE TREATMENTS FOOT, TOE & ANKLE TREATMENTS SHOULDER TREATMENTS AESTHETIC TREATMENTS HIP TREATMENTS ELBOW TREATMENTS HAND & WRIST TREATMENTS BACK PAIN TREATMENT

2025 Interventional Orthobiologics: Latest Research and Product Developments

Interventional orthobiologics research has been progressing rapidly, with numerous studies and product pipelines poised to potentially revolutionize treatment practices. An update for 2024 reveals several ongoing and upcoming trials, which could have significant implications for both physicians and patients in the field.

Importance of Emerging Research

The relevance of these studies lies in their potential to transform clinical practices and treatment options in orthobiologics. For instance, if a company secures FDA approval for stromal vascular fraction (SVF), it could significantly impact the use of bone marrow concentrate (BMC) by providers. Similarly, FDA approval for culture-expanded umbilical cord regenerative stem cells treatment could reshape many treatment protocols. Additionally, a new knee osteoarthritis (OA) injectable drug that halts disease progression would be a game-changer for patients and clinicians alike.

Research Sources and Methodology

The information was gathered from clinicaltrials.gov, focusing on studies involving mesenchymal stem cells (MSCs), SVF, bone marrow aspirate (BMA), BMC, microfragmented adipose tissue (MFat), and exosomes. Disease-specific filters such as knee OA were also used to identify relevant pharmaceutical drug trials. Approximately a thousand entries were reviewed, excluding smaller pilot studies and clinics merely tracking outcomes. The focus was on randomized controlled trials and comparative studies, indexed by their estimated completion dates.

Key Research Studies by Year

2024

Ingeneron: A 40-patient SVF study for wrist OA with a steroid comparator, is expected to be completed by March.
Mayo Clinic: A 30-patient study using SVF for knee osteoarthritis treatment, slated for completion in December.
GID-BIO: A 124-patient knee OA study testing SVF versus placebo, expected by December. This could be an approval study, although the sample size may be a limiting factor.
Lipogems: Multiple studies including an 80-patient study on MFat for meniscal injuries (September), a 173-patient phase III MFat vs. corticosteroid treatment of knee pain OA study (December), and a 30-patient MFat hip OA study in Italy (September).
SyntrFuge: A 173-patient MFat treatment of knee OA study, is expected to be completed by December.
Joint-Stem: A 140-patient phase 2b/3a study on adipose MSCs for knee OA, slated for December. This may not be the final FDA-required trial.
Other notable studies: Various studies from Mayo Clinic, Cleveland Medical Center, iSCLife, BMMMU, Yantai Hospital, Marrow Cellutions, Rizzoli Institute, and others, focusing on knee OA, hip OA, and degenerative disc disease (DDD).

2025

Stanford: Studies on MFat for knee osteoarthritis (March) and shoulder osteoarthritis treatment (December).
University of Utah: Amniotic fluid versus steroid for knee OA in a phase 1/2 study (July).
Biorestorative Therapies: Autologous MSCs for DDD (August).
Atrocell: Phase 3 trial comparing allogeneic MSCs to autologous MSCs and control HA injections (December).
Additional studies: Research from Turkish Grant, Meridigen Biotech, University Medical Center-Ljubljana, Rush University Medical Center, Pagdin Health, Centeno-Schultz Clinic, Lipogems, Tissue Gene, Novartis, Spa Farma, Rizzoli Institute, Mayo Clinic, and GSK, covering a range of orthobiologic treatments.

2026

Ingeneron: A pivotal 246-patient study on rotator cuff tears using an adipose SVF device, delayed to 2026.
Organogenesis: A phase 3 trial of amniotic membrane suspension for knee OA (March).
Personalized Stem Cells: A 260-patient SVF study for knee OA (June).
Additional studies: Research from Cellkine, Rush University Medical Center, Elixcyte, and CellTex, focusing on knee OA, lumbar facet joint arthritis, and various joint OA treatments.

2027-2028

Rizzoli Institute: Studies comparing BMC to hyaluronic acid (HA) for ankle OA and BMC to MFat for knee osteoarthritis, expected by 2027.
Karmy Clinic: A phase 2 study comparing BMA to MFat for hip and knee OA (August 2028).
Genesence: Phase 1b study testing adenovirus vector gene therapy inhibiting IL-1 on knee OA.

Companies Likely to Launch Future Studies

Discgenics: Expected to launch a phase II US study in 2024 after completing phase I studies in the US and Japan.
Other notable experts in the orthobiologics study are Cynata Therapeutics, Organicell, Cells for Cells, Exostemtech, and Ageless Biotech, all of which are involved in various stages of developing orthobiologic treatments.

Summary

While some companies might face delays or financial hurdles, the ongoing and upcoming research in interventional orthobiologics is vast and promising. By the late 2020s, several new treatments and devices could be approved by the FDA, offering enhanced options for clinicians and improved outcomes for patients. The advancements from entities like Italy’s Rizzoli Institute and big pharma’s extensive studies could significantly influence the future landscape of orthobiologic therapies.